Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$20.21 USD
+0.84 (4.34%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $20.39 +0.18 (0.89%) 6:22 PM ET
2-Buy of 5 2
A Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$20.21 USD
+0.84 (4.34%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $20.39 +0.18 (0.89%) 6:22 PM ET
2-Buy of 5 2
A Value B Growth B Momentum A VGM
Zacks News
Otonomy (OTIC) Catches Eye: Stock Jumps 9.1%
by Zacks Equity Research
Otonomy (OTIC) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Verrica (VRCA) in Focus: Stock Moves 8.9% Higher
by Zacks Equity Research
Verrica (VRCA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Top Ranked Momentum Stocks to Buy for July 10th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 10th
The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio
Pacira (PCRX) Provides Preliminary Results for Second Quarter
by Zacks Equity Research
Pacira (PCRX) reports preliminary results for the second quarter of 2020. The company's product sales are hurt by the COVID-19 pandemic. The stock fell in pre-market trading.
4 Small Drug Stocks Worth Betting on Amid Coronavirus Woes
by Zacks Equity Research
Here we discuss four small stocks from the drug sector, which hold potential for a good run amid the coronavirus crisis.
Will Pacira BioSciences Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor of Pacira BioSciences
Pacira (PCRX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Pacira (PCRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why Is Pacira (PCRX) Up 14.6% Since Last Earnings Report?
by Zacks Equity Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PCRX vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PCRX vs. ZTS: Which Stock Is the Better Value Option?
Pacira's (PCRX) Q1 Earnings Top Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira (PCRX) beats on both earnings and revenues in the first quarter of 2020. The company temporarily suspends 2020 guidance in the wake of the COVID-19 pandemic.
Pacira (PCRX) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of 65.62% and 4.52%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Pacira (PCRX) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PCRX or CTLT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PCRX vs. CTLT: Which Stock Is the Better Value Option?
Pacira (PCRX) Down 37.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why You Shouldn't Bet Against Pacira BioSciences (PCRX) Stock
by Zacks Equity Research
Pacira BioSciences (PCRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Pacira (PCRX) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Pacira (PCRX) possesses solid growth attributes, which could help it handily outperform the market.
The Zacks Analyst Blog Highlights: UnitedHealth, Pacira, Turning Point, Coca-Cola and Sempra
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth, Pacira, Turning Point, Coca-Cola and Sempra
PCRX or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PCRX vs. ZTS: Which Stock Is the Better Value Option?
5 Best Stocks to Buy in a Coronavirus-Led Bear Market
by Tirthankar Chakraborty
The period of a typical bear market has a propensity to be pretty lengthy. On average, bear market for the Dow and the S&P 500 lasts 206 and 146 trading days, respectively.
Why Pacira (PCRX) Could Be an Impressive Growth Stock
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Pacira (PCRX)
The Zacks Analyst Blog Highlights: Pacira Pharmaceuticals, Computer Programs and Systems, Mattel and Performance Food Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pacira Pharmaceuticals, Computer Programs and Systems, Mattel and Performance Food Group
Coronavirus Triggers Rate Cut: Stocks That Can Defy Market Fall
by Supriyo Bose
Amid the doom and gloom, we have cherry picked four stocks that possess potential to perform well in the long run.
Spectrum Pharma (SPPI) Incurs Wider-Than-Expected Q4 Loss
by Zacks Equity Research
Spectrum Pharma (SPPI) misses bottom-line estimates for the fourth quarter and records no revenues. Shares down.
3 Reasons Why Pacira (PCRX) Is a Great Growth Stock
by Zacks Equity Research
Pacira (PCRX) could produce exceptional returns because of its solid growth attributes.